$ALXN (Alexion Pharmaceuticals, Inc.)

$ALXN {{ '2015-11-19T15:29:42+0000' | timeago}} • SEC

In 3Q15, upon regulatory approval for Strensiq and Kanuma, $587MM acquired IPR&D assets associated with Strensiq and $4.12Bil of acquired IPR&D assets associated with Kanuma were reclassified from acquired IPR&D to purchased technology. $ALXN has supply agreements with Lonza through 2028 for manufacture of Soliris and Strensiq.

$CRL {{ '2017-07-05T12:50:22+0000' | timeago}} • Announcement

$CRL appointed $ALXN EVP Dr Martin Mackay to its BoD.  As a member of the board, he will serve on the Corporate Governance and Nominating Committee and the Science and Technology Committee.

$ALXN {{ '2017-06-23T12:15:29+0000' | timeago}} • Announcement

$ALXN said it received positive opinion from the Committee for Medicinal Products for Human Use to extend the therapeutic indication for Soliris to include the treatment of refractory generalized myasthenia gravis in patients who are ‘anti-acetylcholine receptor antibody-positive’. A final decision from the European Commission is expected in 3Q17.

$ALXN {{ '2017-06-13T21:27:41+0000' | timeago}} • Announcement

$ALXN appointed Paul Clancy as CFO effective July 31, 2017. Clancy will succeed Dave Anderson, who will continue to serve as CFO until July 31, 2017. To ensure a smooth transition, Anderson will then become a Senior Advisor to the CEO and will remain with the company until the end of August.

$ALXN {{ '2017-06-01T20:48:22+0000' | timeago}} • Announcement

$ALXN announced key additions to its executive leadership team effective June 5, 2017. Reporting to CEO Ludwig Hantson will be: John Orloff, M.D., EVP, Head of Research & Development, Anne-Marie Law, EVP, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., EVP, Chief Compliance Officer.

$ALXN {{ '2017-05-23T13:38:35+0000' | timeago}} • Announcement

$ALXN said Martin Mackay, EVP, Head of Research & Development will be retiring at the end of 2017. A search is also underway for a new Head of R&D with SpencerStuart. Clare Carmichael, EVP, Chief Human Resources Officer, will be leaving to pursue new opportunities effective June 1, 2017. Recruiting is underway for a new Head of Human Resources.

$ALXN {{ '2017-05-23T13:37:23+0000' | timeago}} • Announcement

$ALXN appointed Brian Goff as Chief Commercial Officer, effective June 1, 2017. Goff succeeds Carsten Thiel who is leaving to pursue new opportunities effective June 1, 2017. CFO Dave Anderson will resign his position at the end of August. A search for a new CFO is underway with SpencerStuart.

$ALXN {{ '2017-05-16T11:17:52+0000' | timeago}} • Announcement

$ALXN and The Rady Children's Institute for Genomic Medicine have announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the institute's genomic research expertise with Alexion data science and bioinformatics capabilities.

$ALXN {{ '2017-04-27T16:48:39+0000' | timeago}} • Webcast

$ALXN continues to face challenge in Latin America and expects that to continue in 2017. The company has faced significant setbacks in its attempts to expand Soliris' label in Latin America. The timing of bulk orders, access challenges in Latin America and the impact of ALXN1210 study recruitment will impact 2Q17 and 3Q17 results, said the company.

$ALXN {{ '2017-04-27T14:21:39+0000' | timeago}} • Infographic

$ALXN Alexion Pharmaceuticals Earnings AlphaGraphics: Q1 2017 highlights

$ALXN {{ '2017-04-27T11:43:38+0000' | timeago}} • Announcement

$ALXN reiterated its FY17 total revenue guidance $3.40-3.50Bil. The company increased its GAAP EPS to $2.80-3.20, from $2.55 to $3.05 and non-GAAP EPS to $5.10-5.30, from $5.00-5.25.

$ALXN {{ '2017-04-27T11:39:42+0000' | timeago}} • Announcement

Drugmaker $ALXN reported 85% growth in its 1Q17 earnings, helped by increased revenues. Net income was $170MM, or $0.75 per share, compared to $92MM, or $0.41MM during 1Q16. Revenues rose 24% YoY to $870MM. Excluding items, $ALXN earned $1.38 per share.

$ALXN {{ '2017-03-27T14:02:17+0000' | timeago}} • Announcement

$ALXN BoD appointed Ludwig Hantson, as CEO and member of the BoD, effective immediately. Hantson succeeds David Brennan, who has led the company as Interim CEO since Dec. 2016. Brennan will remain on the BoD.

$ALXN {{ '2017-03-22T20:24:56+0000' | timeago}} • Announcement

$ALXN submitted an application to Japan's Ministry of Labour and Welfare (MHLW) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This is supported by comprehensive Phase 3 REGAIN data.

$ALXN {{ '2017-03-02T21:49:10+0000' | timeago}} • Announcement

$ALXN said Leonard Bell will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders scheduled for May 10, 2017. The Board announced that it expects to appoint David Brennan, Interim CEO and fellow Board member, to succeed Dr. Bell as Chairman.

$ALXN {{ '2017-02-16T15:50:17+0000' | timeago}} • Webcast

$ALXN said that on long term margin expansion, it is going to be positively driven by the long term double digit revenue growth outlook. Also, the company's R&D investment is dependent upon the pipeline opportunities and the ongoing prioritization of investments.

$ALXN {{ '2017-02-16T15:38:20+0000' | timeago}} • Webcast

In Metabolics, $ALXN is guiding revenue of $375-400MM in 2017. The growth for Metabolics is expected to be moderate, mainly in the early part of 2017, due to strong Strensiq performance in 2016, which benefited from patients being identified prior to approval. $ALXN also expects Strensiq revenue per patient to be less than 2016.

$ALXN {{ '2017-02-16T15:35:38+0000' | timeago}} • Webcast

For 2017, $ALXN expects Soliris revenue to be in the $3.025-3.100Bil range and will continue to identify a steady number of new patients with both PNH and aHUS globally. The company also expects the patient recruitment for its ongoing & planned 1210 trials as well as other studies to have a $70-110MM impact headwind on Soliris revenue during 2017.

$ALXN {{ '2017-02-16T15:29:12+0000' | timeago}} • Webcast

$ALXN's net product sales in 2016 rose to about $3.1Bil or 18% YonY. This growth in revenue was helped by a strong 22% increase in volume. Additionally, FY16 Soliris growth was driven by volume growth of 14%, reflecting continued global growth in PNH and aHUS, despite access and treatment interruptions in Latin America.

$ALXN {{ '2017-02-16T15:25:05+0000' | timeago}} • Webcast

$ALXN's Soliris revenue in 4Q16 was $749MM, up 10% YonY, driven by global growth in both PNH and HUS. Strensiq revenue was $71MM, which grew sequential, mostly benefiting from serving newly diagnosed HPP patients. For Kanuma, the company achieved revenue of $11MM.

$ALXN {{ '2017-02-16T15:17:14+0000' | timeago}} • Webcast

$ALXN said that in 2017, the company will deliver continued double digit revenue and non-GAAP EPS growth and is focused on driving operational efficiencies and productivity to expand its operating margin. Additionally, the company also increased its share repurchase authorization to $1Bil.

Recent Transcripts

SRPT (Sarepta Therapeutics, Inc.)
Wednesday, July 19 2017 - 8:30pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Monday, May 8 2017 - 12:30pm
IMGN (ImmunoGen, Inc.)
Friday, May 5 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
SRPT (Sarepta Therapeutics, Inc.)
Thursday, April 27 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
UTHR (United Therapeutics Corporation)
Wednesday, April 26 2017 - 1:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, April 26 2017 - 12:30pm

AlphaGraphics you may like